Company type
Developer of an oral formulation of insulin for intestinal malabsorption in preterm newborns and SBS in infants.Funding rounds
Series D USD 30,000,000
USD 30,000,000 ( )
| Investor | Profile | Country | Notes | |
|---|---|---|---|---|
|
TPG Biotechnology Partners LP | Initial investment. Led the round. | ||
![[current-page:title] logo](/sites/default/files/styles/icon/public/default_images/_no-logo.png?itok=AH4pbDYM){kind=icon}
|
HIG BioHealth Partners | Initial investment. | ||
|
|
WuXi Healthcare Ventures | Initial investment. | ||
|
OrbiMed Advisors LLC | American investment firm focused on making public and private investments in the healthcare and biotechnology industries. | Follow-on investment. | |
|
|
Pontifax | Follow-on investment. |
Investment activity status
Active investor